USOR 24093 - Ph3 study of T-DXd vs SOC gemcitabine for HER2-expressing Biliary Tract Cancer

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer (D781PC00001)

Disease Types: Colorectal/GI/Gastrointestinal

Available at: Arlington Heights, Chicago Resurrection, Niles